Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Q4 2020 · 10-K
Revenue$388.65M$388.65M−1.6% vs Q4 2019 Net Income$92.74M$92.74M+505.4% vs Q4 2019 EPS Diluted$1.09$1.09+505.6% vs Q4 2019 Gross Profit$241,578,000−1.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$80,262,000−10.0% Free Cash Flowderived$71,835,000+7.2% Margins · derivedGross margin62.2%−0.0 pt vs Q4 2019
Operating margin13.5%+4.4 pt vs Q4 2019
Net margin23.9%+20.0 pt vs Q4 2019
ended Dec 31, 2020 · filed Feb 23, 2021 · 54 d after period end